Clinical Trials Using SVN53-67/M57-KLH Peptide Vaccine

Clinical trials are research studies that involve people. The clinical trials on this list are studying SVN53-67/M57-KLH Peptide Vaccine. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • SVN53-67 / M57-KLH Peptide Vaccine in Treating Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

    This phase I trial is to find out the best dose, possible benefits and / or side effects of SVN53-67 / M57-KLH peptide vaccine in incomplete Freund's adjuvant together with sargramostim in treating patients with newly diagnosed multiple myeloma who are receiving lenalidomide maintenance therapy. Vaccines made from survivin peptide may help the body build an effective immune response to kill cancer cells that express survivin. Incomplete Freund's adjuvant may help stimulate the body's immune response to a vaccine treatment. Colony-stimulating factors, such as sargramostim, may increase the production of blood cells. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving SVN53-67 / M57-KLH peptide vaccine in incomplete Freund's adjuvant and sargramostim before or after the start of lenalidomide maintenance therapy may be a better treatment for multiple myeloma.
    Location: 2 locations

  • A Vaccine (SurVaxM) in Treating Patients with Metastatic Neuroendocrine Tumors

    This phase I trial studies the side effects of survivin long peptide vaccine (SurVaxM) and how it works with the immune system in treating patients with neuroendocrine tumors that have spread to other parts of the body (metastatic). Neuroendocrine tumors form from cells that release hormones into the blood in response to a signal from the nervous system. Tumor cells make proteins that are not usually produced by normal cells. The body sees these proteins as not belonging to itself and sends immune cells called T cells to attack the tumor cells that contain these proteins. By vaccinating with small pieces of these proteins called peptides, the immune system can be made to kill tumor cells. Giving survivin long peptide vaccine to patients who have survivin expression in their tumors may create an immune response in the blood that is directed against neuroendocrine tumors.
    Location: Roswell Park Cancer Institute, Buffalo, New York